The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Hypereosinophilic Syndrome

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Hypereosinophilic Syndrome


High impact information on Hypereosinophilic Syndrome


Chemical compound and disease context of Hypereosinophilic Syndrome


Biological context of Hypereosinophilic Syndrome


Anatomical context of Hypereosinophilic Syndrome


Gene context of Hypereosinophilic Syndrome


Analytical, diagnostic and therapeutic context of Hypereosinophilic Syndrome


  1. Premature pulmonary valve opening. Wann, L.S., Weyman, A.E., Dillon, J.C., Feigenbaum, H. Circulation (1977) [Pubmed]
  2. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Klion, A.D., Noel, P., Akin, C., Law, M.A., Gilliland, D.G., Cools, J., Metcalfe, D.D., Nutman, T.B. Blood (2003) [Pubmed]
  3. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Steensma, D.P., Dewald, G.W., Lasho, T.L., Powell, H.L., McClure, R.F., Levine, R.L., Gilliland, D.G., Tefferi, A. Blood (2005) [Pubmed]
  4. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Ostman, A. Cytokine Growth Factor Rev. (2004) [Pubmed]
  5. Troleandomycin and methylprednisolone for treatment of the hypereosinophilic syndrome. Edwards, D., Wald, J.A., Dobozin, B.S., Kirkpatrick, C.H. N. Engl. J. Med. (1987) [Pubmed]
  6. Acute hypereosinophilic syndrome. Successful treatment with vincristine, cytarabine, and prednisone. Van Slyck, E.J., Adamson, T.C. JAMA (1979) [Pubmed]
  7. Human eosinophils express transforming growth factor alpha. Wong, D.T., Weller, P.F., Galli, S.J., Elovic, A., Rand, T.H., Gallagher, G.T., Chiang, T., Chou, M.Y., Matossian, K., McBride, J. J. Exp. Med. (1990) [Pubmed]
  8. Localization of a molecule immunochemically similar to eosinophil major basic protein in human placenta. Maddox, D.E., Kephart, G.M., Coulam, C.B., Butterfield, J.H., Benirschke, K., Gleich, G.J. J. Exp. Med. (1984) [Pubmed]
  9. Lethal host-versus-graft disease and hypereosinophilia in the absence of MHC I-T-cell interactions. Coudert, J.D., Foucras, G., Demur, C., Coureau, C., Mazerolles, C., Delsol, G., Druet, P., Guéry, J.C. J. Clin. Invest. (2000) [Pubmed]
  10. Treatment of hypereosinophilic syndrome with imatinib mesilate. Gleich, G.J., Leiferman, K.M., Pardanani, A., Tefferi, A., Butterfield, J.H. Lancet (2002) [Pubmed]
  11. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Pardanani, A., Reeder, T., Porrata, L.F., Li, C.Y., Tazelaar, H.D., Baxter, E.J., Witzig, T.E., Cross, N.C., Tefferi, A. Blood (2003) [Pubmed]
  12. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Gotlib, J., Cools, J., Malone, J.M., Schrier, S.L., Gilliland, D.G., Coutré, S.E. Blood (2004) [Pubmed]
  13. Effect of docosahexaenoic acid on the generation of platelet-activating factor by eosinophilic leukemia cells, Eol-1. Shikano, M., Masuzawa, Y., Yazawa, K. J. Immunol. (1993) [Pubmed]
  14. Eosinophilic leukemia. Remission with vincristine and hydroxyurea. Chusid, M.J., Dale, D.C. Am. J. Med. (1975) [Pubmed]
  15. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Yamada, Y., Rothenberg, M.E., Lee, A.W., Akei, H.S., Brandt, E.B., Williams, D.A., Cancelas, J.A. Blood (2006) [Pubmed]
  16. Synthesis of interleukin-5 by activated eosinophils in patients with eosinophilic heart diseases. Desreumaux, P., Janin, A., Dubucquoi, S., Copin, M.C., Torpier, G., Capron, A., Capron, M., Prin, L. Blood (1993) [Pubmed]
  17. Eosinophil migration induced by mast cell chymase is mediated by extracellular signal-regulated kinase pathway. Terakawa, M., Tomimori, Y., Goto, M., Hayashi, Y., Oikawa, S., Fukuda, Y. Biochem. Biophys. Res. Commun. (2005) [Pubmed]
  18. Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction. Onitilo, A.A., Kio, E.A., Singh, A.K., Lazarchick, J. Leuk. Lymphoma (2005) [Pubmed]
  19. Differential regulation of the low affinity Fc receptor for IgE (Fc epsilon R2/CD23) and the IL-2 receptor (Tac/p55) on eosinophilic leukemia cell line (EoL-1 and EoL-3). Hosoda, M., Makino, S., Kawabe, T., Maeda, Y., Satoh, S., Takami, M., Mayumi, M., Arai, K., Saitoh, H., Yodoi, J. J. Immunol. (1989) [Pubmed]
  20. Elevated production of interleukin-4 and interleukin-5 by T cells in a child with idiopathic hypereosinophilic syndrome. Takamizawa, M., Iwata, T., Watanabe, K., Hayakawa, H., Takahashi, T., Furue, M., Fukuda, T., Juji, T., Minami, M. J. Allergy Clin. Immunol. (1994) [Pubmed]
  21. High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome. de Lavareille, A., Roufosse, F., Schmid-Grendelmeier, P., Roumier, A.S., Schandené, L., Cogan, E., Simon, H.U., Goldman, M. J. Allergy Clin. Immunol. (2002) [Pubmed]
  22. Hypereosinophilic syndrome human eosinophil degranulation induced by soluble and particulate stimuli. Henderson, W.R., Harley, J.B., Fauci, A.S., Chi, E.Y. Br. J. Haematol. (1988) [Pubmed]
  23. Allogeneic bone marrow transplantation for hypereosinophilic syndrome with advanced myelofibrosis. Sadoun, A., Lacotte, L., Delwail, V., Randriamalala, E., Patri, S., Babin, P., Brizard, A., Guilhot, F. Bone Marrow Transplant. (1997) [Pubmed]
  24. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Cools, J., Quentmeier, H., Huntly, B.J., Marynen, P., Griffin, J.D., Drexler, H.G., Gilliland, D.G. Blood (2004) [Pubmed]
  25. Cloning, chromosomal localization, and RNA expression of a human beta chemokine receptor-like gene. Combadiere, C., Ahuja, S.K., Murphy, P.M. DNA Cell Biol. (1995) [Pubmed]
  26. Induction of eosinophilic granules, nonspecific esterase activity and CD14 expression in the human eosinophilic leukemia cell line, EOL-1. Shintaku, N., Ohshima, Y., Jung, E.Y., Kanazashi, S., Sumimoto, S., Ohmori, K., Heike, T., Katamura, K., Mayumi, M. Hematological oncology. (1994) [Pubmed]
  27. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. Cools, J., DeAngelo, D.J., Gotlib, J., Stover, E.H., Legare, R.D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J.D., Cross, N.C., Tefferi, A., Malone, J., Alam, R., Schrier, S.L., Schmid, J., Rose, M., Vandenberghe, P., Verhoef, G., Boogaerts, M., Wlodarska, I., Kantarjian, H., Marynen, P., Coutre, S.E., Stone, R., Gilliland, D.G. N. Engl. J. Med. (2003) [Pubmed]
  28. A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5. Brugnoni, D., Airó, P., Rossi, G., Bettinardi, A., Simon, H.U., Garza, L., Tosoni, C., Cattaneo, R., Blaser, K., Tucci, A. Blood (1996) [Pubmed]
  29. Human eosinophils can express the cytokines tumor necrosis factor-alpha and macrophage inflammatory protein-1 alpha. Costa, J.J., Matossian, K., Resnick, M.B., Beil, W.J., Wong, D.T., Gordon, J.R., Dvorak, A.M., Weller, P.F., Galli, S.J. J. Clin. Invest. (1993) [Pubmed]
  30. Eosinophils transcribe and translate messenger RNA for inducible nitric oxide synthase. del Pozo, V., de Arruda-Chaves, E., de Andrés, B., Cárdaba, B., López-Farré, A., Gallardo, S., Cortegano, I., Vidarte, L., Jurado, A., Sastre, J., Palomino, P., Lahoz, C. J. Immunol. (1997) [Pubmed]
  31. Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft. Rose, C., Dupire, S., Roche-Lestienne, C., Grardel, N., Bourgeois, E., Cambier, N., Preudhomme, C. Leukemia (2004) [Pubmed]
  32. Marked eosinophilia induced by nafamostat mesilate, an anticoagulant in a hemodialysis patient. Nakanishi, K., Kaneko, T., Yano, F., Horio, M., Kawagoe, H., Fujii, M., Kashiwai, K. Nephron (1992) [Pubmed]
  33. Mastocytosis: pathology, genetics, and current options for therapy. Valent, P., Akin, C., Sperr, W.R., Mayerhofer, M., Födinger, M., Fritsche-Polanz, R., Sotlar, K., Escribano, L., Arock, M., Horny, H.P., Metcalfe, D.D. Leuk. Lymphoma (2005) [Pubmed]
WikiGenes - Universities